These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19636009)

  • 1. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
    J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
    Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
    Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
    Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
    Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
    Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
    QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
    Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
    Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
    J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
    Gedik GK; Hoefnagel CA; Bais E; Olmos RA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
    Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
    Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of High-Specific-Activity
    Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
    J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
    Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
    J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
    Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
    J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma.
    Wakabayashi H; Taki J; Inaki A; Nakamura A; Kayano D; Fukuoka M; Matsuo S; Nakajima K; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):839-46. PubMed ID: 23864328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for refractory pheochromocytoma and paraganglioma after
    Hiromasa T; Wakabayashi H; Kayano D; Inaki A; Watanabe S; Mori H; Akatani N; Yamase T; Kunita Y; Saito S; Kinuya S
    Ann Nucl Med; 2022 Jan; 36(1):61-69. PubMed ID: 34647244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.